Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Bortezomib in Idiopathic Myelofibrosis
2006-001462-16Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- May 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bortezomib in primary myelofibrosis (PMF), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Disease severity response score. Started May 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
primary myelofibrosis (PMF)
Beyond the preview
Go deeper on 2006-001462-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001462-16.